Overview
An experimental anticancer peptide.
In the lab it pokes holes in cancer-cell membranes (which display a protein called HDM-2) while sparing normal cells.
Striking in a dish, but it has never been tested in humans, and the FDA has warned that PNC-27 products are unapproved with no established safety.
This is a research compound, not a therapy.
What It Does
PNC-27 is a synthetic 32-amino-acid peptide combining a p53 (residues 12–26) HDM-2-binding domain with a membrane-penetrating domain.
It binds membrane-expressed HDM-2 on cancer cells, forming transmembrane pores that cause rapid tumor-cell necrosis and mitochondrial disruption; selectively, because normal cells don’t express membrane HDM-2.
All evidence is preclinical (cell/animal).
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 5 mg | + 2.5 mL | 2 mg/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Protocol
Handling & Stacking
- Freeze-dried: -20°F or colder ideal.
- Reconstituted: refrigerate, best used within ~2 weeks (community estimate), kept cold and dark; fragile, potency fades before the 28-day sterility limit.
- Unknown in humans.
- Selective cancer-cell killing in the lab has not been validated as safe or effective in people.
- Supply math Not applicable, no validated human dosing.
- Research compound only.
